Cancer nanomedicine – from the bench to the bedside

Acronym Nano2Clinic
COST action CA17140
Implementation period 28.09.2018. – 27.09.2022.
MC Substitute Dr. Aiva Plotniece
WEB page


Finding efficient cancer therapies is an urgent and still unresolved problem and, in the fight against this disease, scientists are devoting tremendous efforts towards the utilization of nanomedicines. Nanotherapeutics exhibit major benefits with respect to unmodified drugs, including improved half-life, more efficient tumour targeting, and reduced side effects. However, only a few nanotherapeutics have reached the commercial level, most still being in the investigational phase. Accordingly, this Action aims at developing and strengthening industry-academia relations with an ultimate goal: fostering the clinical translation of nanomedicine from bench to bedside. This will be achieved by creating the first, pan-European interdisciplinary network of representatives from academic institutions and small and medium enterprises including clinical research organizations (CROs) devoted to the development of nanosystems carrying anticancer drugs from their initial design, pre-clinical testing of efficacy, pharmacokinetics and toxicity to the preparation of detailed protocols needed for the first phase of their clinical studies. By promoting scientific exchanges, technological implementation and innovative solutions, the Action will provide a timely instrument to rationalize and focus research efforts at the EU level in dealing with the grand challenge of nanomedicine translation in cancer, one of the major and societal-burdening human pathologies. By virtue of its quality, the Action network will also generate research core teams of excellence for funding applications, patent filling and discovery of major scientific impact. The network will also be actively devoted to raising awareness on the high potential on nanomedicine through publications in international peer-reviewed journals, and presentations at open glyconanomaterials for the development of diagnostic tools and targeted therapeutics.

More information can be found at the and|Name:parties